Business
Synlait Buys Pokeno Plant – $307m Deal, Net Loss Reduced
· By Victoria Sterling
| Area |
details |
| sale Impact |
Provides “freedom to move forward” and focus on earning the right to grow over the next six months. |
| Manufacturing issues |
Multiple “micro” issues across engineering,plants,people,and processes – not a single major problem. These were “one-offs”. |
| cost Implications |
Issues in advanced nutrition production quickly increase costs and require support for customers. |
| a2 Milk Relationship |
Trade with a2 Milk (Synlait’s biggest customer) was *not* hindered by the issues. Synlait is currently a2 Milk’s sole infant formula supplier. |
| a2 Milk’s Future Manufacturing |
a2 Milk is becoming its own manufacturer with the purchase of Yashili’s plant in PÅkeno for $282m. |
| SAMR Registration |
Synlait has registration from china’s SAMR to produce China label formula for a2 Milk,renewable in 2027. |
| Production Shift |
a2 Milk’s new plant will likely handle Synlait’s English label product, but Synlait may still have opportunities to produce it. |
| Debt Status |
Synlait is on track to be debt-free by the end of 2026. |
| Future Investment |
The board is expected to be cautious about future investments. CEO would advocate for a debt equity ratio of 20-25%. |
| Sharemarket Reaction |
Synlait shares increased 11.5c to 81.5c following the sale proclamation. |
| Sale Significance |
The sale to Abbott (an existing major customer) is considered a “defining moment” for Synlait. |
Related